Minerva gastroenterology最新文献_第5页

Epidemiology and clinical course of late onset inflammatory bowel disease. 晚发性炎症性肠病的流行病学和临床过程。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2021-05-31 DOI: 10.23736/S2724-5985.21.02890-4

Anna Viola, Gionata Fiorino, Giuseppe Costantino, Walter Fries

引用次数: 0

Study on the effect of cartoon video education before orbital operation. 轨道手术前卡通视频教育效果研究。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-05-26 DOI: 10.23736/S2724-5985.23.03441-1

Xiufen Lian, Meimiao Tan, Huiqi Zeng, Huijing Ye

引用次数: 0

Curcumin inhibits liver cancer by regulating Bcl-9/β-catenin pathway. 姜黄素通过调节 Bcl-9/β-catenin 通路抑制肝癌。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-06-30 DOI: 10.23736/S2724-5985.23.03476-9

Gang Wang, Meng Lu, Hongyan Jia

引用次数: 0

Clinical study of HAIC via left distal branchial radial artery route in the treatment of liver tumors. 经左侧桡动脉远端分支途径进行 HAIC 治疗肝肿瘤的临床研究。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-07-27 DOI: 10.23736/S2724-5985.23.03514-3

Zhengqing Hu, Yu Liu, Jianjun Jiang, Wenbin Hu, Jianhao Ou, Tian Tang

引用次数: 0

Observation of therapeutic effect of inhaled N-acetylcysteine pulmonary lavage in patients with severe pneumonia. 观察吸入 N-乙酰半胱氨酸肺灌洗对重症肺炎患者的治疗效果。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-08-03 DOI: 10.23736/S2724-5985.23.03500-3

Zhihong Song, Xiaoqian Xu, Yuan Zhang, Yanqiong Zhao

引用次数: 0

Clinical application analysis of comfort nursing in the care of patients with acute cholecystitis. 舒适护理在急性胆囊炎患者护理中的临床应用分析。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-07-27 DOI: 10.23736/S2724-5985.23.03515-5

Qi Guo, Yu Wang, Lijun Huo, Di Shen, Linlin Shi, Hua Ling, Peifang Wu, Yan Song

引用次数: 0

Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients. 治疗老年炎症性肠病的免疫抑制剂的安全性和潜在相互作用。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2021-05-31 DOI: 10.23736/S2724-5985.21.02919-3

Ylenia Ingrasciotta, Mauro Grova, Federica Crispino, Valentina Isgrò, Fabrizio Calapai, Fabio S Macaluso, Francesco Mattace-Raso, Gianluca Trifirò, Ambrogio Orlando

{"title":"Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients.","authors":"Ylenia Ingrasciotta, Mauro Grova, Federica Crispino, Valentina Isgrò, Fabrizio Calapai, Fabio S Macaluso, Francesco Mattace-Raso, Gianluca Trifirò, Ambrogio Orlando","doi":"10.23736/S2724-5985.21.02919-3","DOIUrl":"10.23736/S2724-5985.21.02919-3","url":null,"abstract":"Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic diseases associated with increased morbidity and reduced quality of life. Age may represent a risk factor for adverse events, due to the multimorbidity and polypharmacy, common in elderly patients. Elderly are often not included in clinical trials evaluating efficacy and safety of study drugs for the treatment of inflammatory bowel diseases. Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppressant drugs, biological drugs and Janus Kinase inhibitors, are available for the management of inflammatory bowel diseases. Therefore, with the increasing spectrum of therapeutic options it is important to analyze the evidence regarding the safety of the use of these agents in elderly patients. Selection of immunosuppressive therapy is a challenge in the management of elderly patients with inflammatory bowel diseases, for whom biologics with a lower risk of infection or cancer, such as vedolizumab and ustekinumab, may be preferred in elderly patients. Concomitant therapies and comorbidities must be thoroughly investigated before initiating any immunosuppressive or biological therapy in order to minimize the risk of drug-drug interactions. This review aimed to provide an overview of the safety of thiopurines, methotrexate and target therapies as well as their drug-drug interactions in patients with inflammatory bowel diseases.","PeriodicalId":18653,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"98-108"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39036401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between STAP1 methylation in peripheral blood T cells and the clinicopathological characteristics and prognosis of patients within 5-cm diameter HCC. 外周血 T 细胞中 STAP1 甲基化与直径在 5 厘米以内的 HCC 患者的临床病理特征和预后之间的关系。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-08-01 DOI: 10.23736/S2724-5985.23.03309-0

Libo Sun, Xiaofei Zhao, Haitao Zhang, Guangming Li, Ning Li

{"title":"Relationship between STAP1 methylation in peripheral blood T cells and the clinicopathological characteristics and prognosis of patients within 5-cm diameter HCC.","authors":"Libo Sun, Xiaofei Zhao, Haitao Zhang, Guangming Li, Ning Li","doi":"10.23736/S2724-5985.23.03309-0","DOIUrl":"10.23736/S2724-5985.23.03309-0","url":null,"abstract":"Background: The aim of this study is to explore the methylation of signal transduction adaptor protein 1 (STAP1) in peripheral blood T cells as a prognostic marker for hepatocellular carcinoma (HCC) ≤5 cm.Methods: A total of 66 HCC patients who visited our hospital from November 2012 to June 2016 were retrospectively analyzed, and 55 patients who met the inclusion and exclusion criteria were studied. Clinical and pathological data were collected from all patients to detect STAP1 methylation. STAP1 methylation expression was analyzed in HCC patients ≤5 cm with different clinicopathological features; univariate and independent prognostic factors were analyzed in HCC patients; and the relationship between STAP1 methylation expression and prognosis was analyzed in HCC patients.Results: There was no significant difference in STAP1 methylation expression between patients with different gender, age, history of alcoholism, history of liver cirrhosis, recurrence, 3-year OS, 5-year OS, treatment, number of tumors, tumor diameter, HBV-DNA, HBSAg, Hbe-Ag expression, and AFP level (P>0.05); however, there was significant difference in STAP1 methylation expression between patients with different survival, 3-year DFS, and 5-year DFS (P<0.05). Multivariate Cox regression analysis showed that recurrence and STAP1 methylation were independent factors for OS and DFS (P<0.05). Kaplan-Meier survival curve results showed that the median survival time, OS, and DFS of STAP1 hypermethylation expression were shorter than those of hypomethylation (P<0.05).Conclusions: STAP1 methylation in peripheral blood T cells serves as a potential prognostic marker for HCC ≤5 cm.","PeriodicalId":18653,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"16-21"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10269458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

To investigate the changes in colonic pouch function and retention rate after ileal pouch-anal anastomosis in elderly patients with ulcerative colitis: a multicenter retrospective analysis. 研究老年溃疡性结肠炎患者回肠袋-肛门吻合术后结肠袋功能和留置率的变化：一项多中心回顾性分析。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-06-20 DOI: 10.23736/S2724-5985.23.03454-X

Kaiqiang He, Zhuang Yu, Yuan Wu

引用次数: 0

Xerostomia and prevention of dryness with a Pycnogenol® mouth spray: a pilot study. 口腔干燥症和使用 Pycnogenol® 口腔喷雾剂预防口腔干燥：一项试点研究。

IF 3 4区医学

Minerva gastroenterology Pub Date : 2024-03-01 Epub Date: 2023-05-10 DOI: 10.23736/S2724-5985.22.03245-4

Maria R Cesarone, Gianni Belcaro, Claudia Scipione, Valeria Scipione, Mark Dugall, Shu Hu, Beatrice Feragalli, Roberto Cotellese

{"title":"Xerostomia and prevention of dryness with a Pycnogenol® mouth spray: a pilot study.","authors":"Maria R Cesarone, Gianni Belcaro, Claudia Scipione, Valeria Scipione, Mark Dugall, Shu Hu, Beatrice Feragalli, Roberto Cotellese","doi":"10.23736/S2724-5985.22.03245-4","DOIUrl":"10.23736/S2724-5985.22.03245-4","url":null,"abstract":"Background: The aim of this pilot, supplement study was the evaluation of primary, idiopathic mucosal mouth dryness (xerostomia or dry mouth) in subjects without systemic diseases.Methods: Subjects with xerostomia were managed either with standard management (SM) or with SM and a Pycnogenol® mouth spray (Hankintatukku Oy, Karkkila, Finland), at the dosage of 60 mg/day in 30 spurts, for 2 weeks.Results: A total of 50 subjects were included in the study: 25 controls using only standard management (SM) and 25 subjects using the Pycnogenol® mouth spray. No side effects and no tolerability problems were observed with the Pycnogenol® mouth spray. The groups were comparable for characteristics and symptoms at baseline. These otherwise healthy subjects had a BMI<26. After 2 weeks, salivary flow and salivary oxidative stress (in Carr Units) were improved significantly with Pycnogenol® mouth spray as compared to controls (P<0.05), whereas minimal improvements in salivary flow were seen with SM. The subjective symptomatic dry mouth score and the number of mucosal breaks and ulcerations (all minimal, <1 mm in length or diameter) were significantly decreased with the Pycnogenol® mouth spray supplement compared to SM controls (P<0.05). The Pycnogenol® mouth spray led to significant improvement in salivary lysozyme levels, compared to controls (P<0.05).Conclusions: Based on these preliminary results, Pycnogenol® mouth spray could be a new supplementary option for the management of primary xerostomia.","PeriodicalId":18653,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"36-41"},"PeriodicalIF":3.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9439002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0